Suzuki Hidekazu, Hirashima Tomonori, Kobayashi Masashi, Okamoto Norio, Matsuura Yuka, Tamiya Motohiro, Morishita Naoko, Okafuji Kohei, Shiroyama Takayuki, Morimura Osamu, Morita Satomu, Kawase Ichiro
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan.
Intern Med. 2012;51(7):707-10. doi: 10.2169/internalmedicine.51.6236. Epub 2012 Apr 1.
The incidence of malignant pleural mesothelioma (MPM) in Japan is predicted to increase over the next few decades. Prognostic factors remain unclear although several studies have reported this disease. In this study, we examined the prognostic factors of MPM from single institution practice data and tested the scoring systems of past reports.
We retrospectively obtained clinical data from the medical records of patients who were diagnosed with MPM from 1991 to 2010. The European Organization for Research and Treatment of Cancer prognostic score (EPS) was calculated.
We surveyed the records of 68 patients. Univariate analysis showed that significant prognostic factors were histological type, stage, performance status (PS), chemotherapy, and lactate dehydrogenase (LD). Multivariate analysis identified stage, PS and LD as independent prognostic factors. Low-risk group (EPS ≤1.27) survival was significantly better than that of the high-risk group (EPS >1.27) (17.0 months vs. 8.0 months; p=0.002).
Stage, PS and LD were demonstrated to be independent prognostic factors. An EPS >1.27 was still considered a poor prognosis indicator in the practice data of MPM.
预计在未来几十年里,日本恶性胸膜间皮瘤(MPM)的发病率将会上升。尽管已有多项研究报道了这种疾病,但其预后因素仍不明确。在本研究中,我们从单机构实践数据中分析了MPM的预后因素,并对既往报道的评分系统进行了验证。
我们回顾性收集了1991年至2010年期间确诊为MPM的患者的病历临床资料,并计算了欧洲癌症研究与治疗组织预后评分(EPS)。
我们调查了68例患者的记录。单因素分析显示,显著的预后因素包括组织学类型、分期、体能状态(PS)、化疗和乳酸脱氢酶(LD)。多因素分析确定分期、PS和LD为独立预后因素。低风险组(EPS≤1.27)的生存期显著优于高风险组(EPS>1.27)(17.0个月对8.0个月;p=0.002)。
分期、PS和LD被证实为独立预后因素。在MPM的实践数据中,EPS>1.27仍被认为是预后不良的指标。